Jama Pitman - Feb 15, 2024 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
SVP, Chief Development Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Feb 15, 2024
Transactions value $
-$35,405
Form type
4
Date filed
2/20/2024, 04:05 PM
Previous filing
Jan 18, 2024
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +9.73K +19.23% $0.00 60.3K Feb 15, 2024 Direct F1
transaction DCPH Common Stock Award $0 +10K +16.58% $0.00 70.3K Feb 15, 2024 Direct F2
transaction DCPH Common Stock Sale -$35.4K -2.27K -3.22% $15.62 68K Feb 16, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +38.9K $0.00 38.9K Feb 15, 2024 Common Stock 38.9K $15.92 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 9,725 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027.
F2 The reporting person was awarded 10,000 RSUs. These RSUs shall vest in two equal annual installments on each of February 15, 2025 and February 15, 2026.
F3 This sale was to cover tax liabilities in the vesting of RSUs.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6175 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024.